206 related articles for article (PubMed ID: 21873531)
1. An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus.
Ahuja A; Teichmann LL; Wang H; Dunn R; Kehry MR; Shlomchik MJ
J Immunol; 2011 Oct; 187(7):3888-94. PubMed ID: 21873531
[TBL] [Abstract][Full Text] [Related]
2. Depletion of B cells in murine lupus: efficacy and resistance.
Ahuja A; Shupe J; Dunn R; Kashgarian M; Kehry MR; Shlomchik MJ
J Immunol; 2007 Sep; 179(5):3351-61. PubMed ID: 17709552
[TBL] [Abstract][Full Text] [Related]
3. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
Marinov AD; Wang H; Bastacky SI; van Puijenbroek E; Schindler T; Speziale D; Perro M; Klein C; Nickerson KM; Shlomchik MJ
Arthritis Rheumatol; 2021 May; 73(5):826-836. PubMed ID: 33277983
[TBL] [Abstract][Full Text] [Related]
4. Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche.
Wang W; Rangel-Moreno J; Owen T; Barnard J; Nevarez S; Ichikawa HT; Anolik JH
J Immunol; 2014 Apr; 192(7):3011-20. PubMed ID: 24574498
[TBL] [Abstract][Full Text] [Related]
5. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.
Bekar KW; Owen T; Dunn R; Ichikawa T; Wang W; Wang R; Barnard J; Brady S; Nevarez S; Goldman BI; Kehry M; Anolik JH
Arthritis Rheum; 2010 Aug; 62(8):2443-57. PubMed ID: 20506300
[TBL] [Abstract][Full Text] [Related]
6. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
[TBL] [Abstract][Full Text] [Related]
7. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice.
Merino R; Iwamoto M; Fossati L; Izui S
J Immunol; 1993 Dec; 151(11):6509-16. PubMed ID: 7902378
[TBL] [Abstract][Full Text] [Related]
8. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
9. Administration of adenovirus encoding anti-CD20 antibody gene induces B-cell deletion and alleviates lupus in the BWF1 mouse model.
Wang C; Wang M; Liu Y; Zeng P
Int Immunopharmacol; 2011 Jun; 11(6):693-7. PubMed ID: 21272677
[TBL] [Abstract][Full Text] [Related]
10. AID dysregulation in lupus-prone MRL/Fas(lpr/lpr) mice increases class switch DNA recombination and promotes interchromosomal c-Myc/IgH loci translocations: modulation by HoxC4.
White CA; Seth Hawkins J; Pone EJ; Yu ES; Al-Qahtani A; Mai T; Zan H; Casali P
Autoimmunity; 2011 Dec; 44(8):585-98. PubMed ID: 21585311
[TBL] [Abstract][Full Text] [Related]
11. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
[TBL] [Abstract][Full Text] [Related]
12. Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
Kneitz C; Wilhelm M; Tony HP
Immunobiology; 2002 Dec; 206(5):519-27. PubMed ID: 12607727
[TBL] [Abstract][Full Text] [Related]
13. B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus.
Wen J; Doerner J; Chalmers S; Stock A; Wang H; Gullinello M; Shlomchik MJ; Putterman C
J Neuroinflammation; 2016 Apr; 13(1):73. PubMed ID: 27055816
[TBL] [Abstract][Full Text] [Related]
14. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
Tanaka Y
Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
[No Abstract] [Full Text] [Related]
15. Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration.
Licht R; van Bruggen MC; Oppers-Walgreen B; Rijke TP; Berden JH
Arthritis Rheum; 2001 Jun; 44(6):1320-30. PubMed ID: 11407691
[TBL] [Abstract][Full Text] [Related]
16. Rituximab - shadow, illusion or light?
van Vollenhoven RF
Autoimmun Rev; 2012 Jun; 11(8):563-7. PubMed ID: 22036829
[TBL] [Abstract][Full Text] [Related]
17. Anti-class a scavenger receptor autoantibodies from systemic lupus erythematosus patients impair phagocytic clearance of apoptotic cells by macrophages in vitro.
Chen XW; Shen Y; Sun CY; Wu FX; Chen Y; Yang CD
Arthritis Res Ther; 2011 Jan; 13(1):R9. PubMed ID: 21281474
[TBL] [Abstract][Full Text] [Related]
18. Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?
Gorman C; Leandro M; Isenberg D
Lupus; 2004; 13(5):312-6. PubMed ID: 15230284
[TBL] [Abstract][Full Text] [Related]
19. Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies.
Grandjean CL; Montalvao F; Celli S; Michonneau D; Breart B; Garcia Z; Perro M; Freytag O; Gerdes CA; Bousso P
Sci Rep; 2016 Oct; 6():34382. PubMed ID: 27698437
[TBL] [Abstract][Full Text] [Related]
20. Regulation of basement membrane-reactive B cells in BXSB, (NZBxNZW)F1, NZB, and MRL/lpr lupus mice.
Clark AG; Fan Q; Brady GF; Mackin KM; Coffman ED; Weston ML; Foster MH
Autoimmunity; 2013 May; 46(3):188-204. PubMed ID: 23157336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
